<p>Ultragenyx Pharmaceutical（纳斯达克代码：RARE - 获取免费报告）在周日发布给投资者的报告中，被华尔街 Zen 从 “卖出” 评级上调至 “持有” 评级。</p>
<ul>
<li>分析师表示这两家中型生物科技公司具有两倍的潜力</li>
</ul>
<p>其他几位股票研究分析师也最近对该公司发表了看法。Truist Financial 在 3 月 25 日的报告中将 Ultragenyx Pharmaceutical 的评级上调至 “强力买入”。Guggenheim 在 1 月 5 日的报告中将 Ultragenyx Pharmaceutical 的目标价从 64.00 美元下调至 52.00 美元，并给予该公司 “买入” 评级。摩根大通在 3 月 12 日的报告中将 Ultragenyx Pharmaceutical 的目标价从 120.00 美元下调至 74.00 美元，并给予该公司 “增持” 评级。高盛在 3 月 24 日的报告中将 Ultragenyx Pharmaceutical 的评级从 “买入” 下调至 “中性”，并将其股票目标价从 61.00 美元下调至 25.00 美元。最后，Wedbush 在 2 月 17 日的报告中重申了 “中性” 评级，并对 Ultragenyx Pharmaceutical 的股票设定了 25.00 美元的目标价。一位股票研究分析师给予该股票 “强力买入” 评级，十四位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 60.76 美元。</p>
<p><strong>查看我们关于 Ultragenyx Pharmaceutical 的最新股票报告</strong></p>
<h2>Ultragenyx Pharmaceutical 股票表现</h2>
<p>纳斯达克 RARE 周五开盘价为 24.77 美元。该股票的 50 日移动平均价格为 22.50 美元，200 日移动平均价格为 26.99 美元。Ultragenyx Pharmaceutical 的年低为 18.29 美元，年高为 42.37 美元。该公司的市值为 24.4 亿美元，市盈率为-4.24，贝塔值为 0.38。</p>
<p>Ultragenyx Pharmaceutical（纳斯达克代码：RARE - 获取免费报告）最近于 2 月 12 日发布了其财报。这家生物制药公司报告每股收益（EPS）为-1.29 美元，低于市场共识预期的-1.20 美元，差距为 0.09 美元。Ultragenyx Pharmaceutical 的净利润率为-85.54%，股本回报率为-1,024.42%。该公司在本季度的收入为 2.0728 亿美元，而分析师预期为 1.9960 亿美元。去年同期，该公司每股收益为-1.39 美元。Ultragenyx Pharmaceutical 本季度的收入同比增长 25.5%。整体来看，股票分析师预测 Ultragenyx Pharmaceutical 在当前财政年度的每股收益为-4.49 美元。</p>
<h2>内部人士下注</h2>
<p>在其他 Ultragenyx Pharmaceutical 的新闻中，执行副总裁 Eric Crombez 于 3 月 2 日的交易中出售了 7,029 股该公司的股票。该股票以平均价格 22.80 美元出售，总价值为 160,261.20 美元。出售完成后，该执行副总裁持有 76,301 股公司股票，价值约为 1,739,662.80 美元。这笔交易代表其持股减少了 8.44%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，首席执行官 Emil D. Kakkis 于 3 月 2 日的交易中出售了 54,404 股 Ultragenyx Pharmaceutical 的股票。该股票以平均价格 22.80 美元出售，总价值为 1,240,411.20 美元。出售后，首席执行官直接持有 658,994 股公司股票，价值为 15,025,063.20 美元。这笔交易代表其持股减少了 7.63%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士已出售 109,556 股公司股票，价值为 2,490,138 美元。当前 5.20% 的股票由公司内部人士持有。</p>
<h2>Ultragenyx Pharmaceutical 的机构交易</h2>
<p>机构投资者和对冲基金最近买卖了该公司的股票。Aquatic Capital Management LLC 在第三季度将其在 Ultragenyx Pharmaceutical 的股份增加了 79.1%。Aquatic Capital Management LLC 目前持有 191,458 股该生物制药公司的股票，价值为 5,759,000 美元，此前在该期间内又收购了 84,559 股。SG Americas Securities LLC 在第三季度收购了 Ultragenyx Pharmaceutical 的新股份，价值约为 3,773,000 美元。Aberdeen Group plc 在第三季度将其在 Ultragenyx Pharmaceutical 的股份增加了 94.3%。Aberdeen Group plc 目前持有 973,656 股该生物制药公司的股票，价值为 29,288,000 美元，此前在该期间内又收购了 472,600 股。WCM Investment Management LLC 在第三季度将其在 Ultragenyx Pharmaceutical 的股份增加了 36.9%。WCM Investment Management LLC 目前持有 288,109 股该生物制药公司的股票，价值为 8,747,000 美元，此前在该期间内又收购了 77,640 股。最后，Thornburg Investment Management Inc.在第三季度收购了 Ultragenyx Pharmaceutical 的新股份，价值约为 2,083,000 美元。当前 97.67% 的股票由机构投资者和对冲基金持有。</p>
<h2>Ultragenyx Pharmaceutical 公司简介</h2>
<p>（获取免费报告）</p>
<p>Ultragenyx Pharmaceutical Inc 是一家生物制药公司，专注于开发和商业化针对罕见和超罕见遗传疾病的疗法。自 2010 年成立以来，总部位于加利福尼亚州诺瓦托，该公司在蛋白质替代疗法、小分子和基因疗法方面积累了专业知识，以应对高度未满足的医疗需求。Ultragenyx 采用精准医学模型，利用内部研究和战略合作来推进其产品管道，从发现到监管批准。</p>
<p>该公司的商业产品组合包括用于 X 连锁低磷血症的 Crysvita（burosumab-tmyl）、用于粘多糖贮积症 VII 的 Mepsevii（vestronidase alfa-vjbk）以及用于长链脂肪酸氧化障碍的 Dojolvi（triheptanoin）。</p>
<h2>了解更多</h2>
<ul>
<li>五只我们认为比 Ultragenyx Pharmaceutical 更好的股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFSRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFSRQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Ultragenyx Pharmaceutical 吗？</h2>
<p>在考虑 Ultragenyx Pharmaceutical 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Ultragenyx Pharmaceutical 并不在名单上。</p>
<p>虽然 Ultragenyx Pharmaceutical 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Ultragenyx制药

标普全球医疗股指数 ETF - iShares

美国制药 ETF - iShares

<p>华尔街禅将 Ultragenyx 制药（NASDAQ:RARE）的评级从 “卖出” 上调至 “持有”。其他分析师的看法不一，Truist Financial 给予 “强力买入” 评级，而高盛则将其下调至 “中性”。该股票开盘价为 24.77 美元，市值为 24.4 亿美元。最近的财报显示每股亏损为（1.29 美元），但收入同比增长了 25.5%。内部人士最近出售了股份，而机构投资者则增加了对公司的持股</p>

<p>Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) was upgraded by Wall Street Zen from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a note issued to investors on Sunday.</p>
<div class="lb-trans"><p>Ultragenyx Pharmaceutical（纳斯达克代码：RARE - 获取免费报告）在周日发布给投资者的报告中，被华尔街 Zen 从 “卖出” 评级上调至 “持有” 评级。</p>
</div><ul>
<li>Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师表示这两家中型生物科技公司具有两倍的潜力</li>
</ul>
</div><p>Several other equities research analysts also recently weighed in on the company. Truist Financial raised Ultragenyx Pharmaceutical to a &#34;strong-buy&#34; rating in a report on Wednesday, March 25th. Guggenheim lowered their price target on Ultragenyx Pharmaceutical from $64.00 to $52.00 and set a &#34;buy&#34; rating for the company in a report on Monday, January 5th. JPMorgan Chase &amp; Co. lowered their price target on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an &#34;overweight&#34; rating for the company in a report on Thursday, March 12th. The Goldman Sachs Group downgraded Ultragenyx Pharmaceutical from a &#34;buy&#34; rating to a &#34;neutral&#34; rating and lowered their price target for the stock from $61.00 to $25.00 in a report on Tuesday, March 24th. Finally, Wedbush reissued a &#34;neutral&#34; rating and issued a $25.00 price target on shares of Ultragenyx Pharmaceutical in a report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $60.76.</p>
<div class="lb-trans"><p>其他几位股票研究分析师也最近对该公司发表了看法。Truist Financial 在 3 月 25 日的报告中将 Ultragenyx Pharmaceutical 的评级上调至 “强力买入”。Guggenheim 在 1 月 5 日的报告中将 Ultragenyx Pharmaceutical 的目标价从 64.00 美元下调至 52.00 美元，并给予该公司 “买入” 评级。摩根大通在 3 月 12 日的报告中将 Ultragenyx Pharmaceutical 的目标价从 120.00 美元下调至 74.00 美元，并给予该公司 “增持” 评级。高盛在 3 月 24 日的报告中将 Ultragenyx Pharmaceutical 的评级从 “买入” 下调至 “中性”，并将其股票目标价从 61.00 美元下调至 25.00 美元。最后，Wedbush 在 2 月 17 日的报告中重申了 “中性” 评级，并对 Ultragenyx Pharmaceutical 的股票设定了 25.00 美元的目标价。一位股票研究分析师给予该股票 “强力买入” 评级，十四位给予 “买入” 评级，两位给予 “持有” 评级，一位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，平均目标价为 60.76 美元。</p>
</div><p><strong>View Our Latest Stock Report on Ultragenyx Pharmaceutical</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Ultragenyx Pharmaceutical 的最新股票报告</strong></p>
</div><h2>Ultragenyx Pharmaceutical Stock Performance</h2>
<div class="lb-trans"><h2>Ultragenyx Pharmaceutical 股票表现</h2>
</div><p>NASDAQ RARE opened at $24.77 on Friday. The stock has a 50 day moving average price of $22.50 and a 200-day moving average price of $26.99. Ultragenyx Pharmaceutical has a one year low of $18.29 and a one year high of $42.37. The company has a market capitalization of $2.44 billion, a P/E ratio of -4.24 and a beta of 0.38.</p>
<div class="lb-trans"><p>纳斯达克 RARE 周五开盘价为 24.77 美元。该股票的 50 日移动平均价格为 22.50 美元，200 日移动平均价格为 26.99 美元。Ultragenyx Pharmaceutical 的年低为 18.29 美元，年高为 42.37 美元。该公司的市值为 24.4 亿美元，市盈率为-4.24，贝塔值为 0.38。</p>
</div><p>Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The company had revenue of $207.28 million during the quarter, compared to analysts' expectations of $199.60 million. During the same quarter last year, the firm earned ($1.39) EPS. Ultragenyx Pharmaceutical's revenue for the quarter was up 25.5% on a year-over-year basis. As a group, equities analysts predict that Ultragenyx Pharmaceutical will post -4.49 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Ultragenyx Pharmaceutical（纳斯达克代码：RARE - 获取免费报告）最近于 2 月 12 日发布了其财报。这家生物制药公司报告每股收益（EPS）为-1.29 美元，低于市场共识预期的-1.20 美元，差距为 0.09 美元。Ultragenyx Pharmaceutical 的净利润率为-85.54%，股本回报率为-1,024.42%。该公司在本季度的收入为 2.0728 亿美元，而分析师预期为 1.9960 亿美元。去年同期，该公司每股收益为-1.39 美元。Ultragenyx Pharmaceutical 本季度的收入同比增长 25.5%。整体来看，股票分析师预测 Ultragenyx Pharmaceutical 在当前财政年度的每股收益为-4.49 美元。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Ultragenyx Pharmaceutical news, EVP Eric Crombez sold 7,029 shares of the firm's stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $160,261.20. Following the completion of the sale, the executive vice president owned 76,301 shares of the company's stock, valued at approximately $1,739,662.80. This trade represents a 8.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through the SEC website. Also, CEO Emil D. Kakkis sold 54,404 shares of Ultragenyx Pharmaceutical stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $1,240,411.20. Following the sale, the chief executive officer directly owned 658,994 shares of the company's stock, valued at $15,025,063.20. This trade represents a 7.63% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders have sold 109,556 shares of company stock valued at $2,490,138. 5.20% of the stock is currently owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Ultragenyx Pharmaceutical 的新闻中，执行副总裁 Eric Crombez 于 3 月 2 日的交易中出售了 7,029 股该公司的股票。该股票以平均价格 22.80 美元出售，总价值为 160,261.20 美元。出售完成后，该执行副总裁持有 76,301 股公司股票，价值约为 1,739,662.80 美元。这笔交易代表其持股减少了 8.44%。该出售在与证券交易委员会的法律文件中披露，相关信息可通过 SEC 网站访问。此外，首席执行官 Emil D. Kakkis 于 3 月 2 日的交易中出售了 54,404 股 Ultragenyx Pharmaceutical 的股票。该股票以平均价格 22.80 美元出售，总价值为 1,240,411.20 美元。出售后，首席执行官直接持有 658,994 股公司股票，价值为 15,025,063.20 美元。这笔交易代表其持股减少了 7.63%。有关此次出售的更多细节可在官方 SEC 披露中找到。在过去 90 天内，内部人士已出售 109,556 股公司股票，价值为 2,490,138 美元。当前 5.20% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Trading of Ultragenyx Pharmaceutical</h2>
<div class="lb-trans"><h2>Ultragenyx Pharmaceutical 的机构交易</h2>
</div><p>Institutional investors and hedge funds have recently bought and sold shares of the business. Aquatic Capital Management LLC lifted its stake in Ultragenyx Pharmaceutical by 79.1% during the 3rd quarter. Aquatic Capital Management LLC now owns 191,458 shares of the biopharmaceutical company's stock valued at $5,759,000 after acquiring an additional 84,559 shares during the period. SG Americas Securities LLC acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $3,773,000. Aberdeen Group plc lifted its stake in Ultragenyx Pharmaceutical by 94.3% during the 3rd quarter. Aberdeen Group plc now owns 973,656 shares of the biopharmaceutical company's stock valued at $29,288,000 after acquiring an additional 472,600 shares during the period. WCM Investment Management LLC lifted its stake in Ultragenyx Pharmaceutical by 36.9% during the 3rd quarter. WCM Investment Management LLC now owns 288,109 shares of the biopharmaceutical company's stock valued at $8,747,000 after acquiring an additional 77,640 shares during the period. Finally, Thornburg Investment Management Inc. acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter valued at approximately $2,083,000. 97.67% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近买卖了该公司的股票。Aquatic Capital Management LLC 在第三季度将其在 Ultragenyx Pharmaceutical 的股份增加了 79.1%。Aquatic Capital Management LLC 目前持有 191,458 股该生物制药公司的股票，价值为 5,759,000 美元，此前在该期间内又收购了 84,559 股。SG Americas Securities LLC 在第三季度收购了 Ultragenyx Pharmaceutical 的新股份，价值约为 3,773,000 美元。Aberdeen Group plc 在第三季度将其在 Ultragenyx Pharmaceutical 的股份增加了 94.3%。Aberdeen Group plc 目前持有 973,656 股该生物制药公司的股票，价值为 29,288,000 美元，此前在该期间内又收购了 472,600 股。WCM Investment Management LLC 在第三季度将其在 Ultragenyx Pharmaceutical 的股份增加了 36.9%。WCM Investment Management LLC 目前持有 288,109 股该生物制药公司的股票，价值为 8,747,000 美元，此前在该期间内又收购了 77,640 股。最后，Thornburg Investment Management Inc.在第三季度收购了 Ultragenyx Pharmaceutical 的新股份，价值约为 2,083,000 美元。当前 97.67% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Ultragenyx Pharmaceutical Company Profile</h2>
<div class="lb-trans"><h2>Ultragenyx Pharmaceutical 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.</p>
<div class="lb-trans"><p>Ultragenyx Pharmaceutical Inc 是一家生物制药公司，专注于开发和商业化针对罕见和超罕见遗传疾病的疗法。自 2010 年成立以来，总部位于加利福尼亚州诺瓦托，该公司在蛋白质替代疗法、小分子和基因疗法方面积累了专业知识，以应对高度未满足的医疗需求。Ultragenyx 采用精准医学模型，利用内部研究和战略合作来推进其产品管道，从发现到监管批准。</p>
</div><p>The company's commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.</p>
<div class="lb-trans"><p>该公司的商业产品组合包括用于 X 连锁低磷血症的 Crysvita（burosumab-tmyl）、用于粘多糖贮积症 VII 的 Mepsevii（vestronidase alfa-vjbk）以及用于长链脂肪酸氧化障碍的 Dojolvi（triheptanoin）。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Ultragenyx Pharmaceutical</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们认为比 Ultragenyx Pharmaceutical 更好的股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkFSRQ" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=RARE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Ultragenyx Pharmaceutical Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Ultragenyx Pharmaceutical 吗？</h2>
</div><p>Before you consider Ultragenyx Pharmaceutical, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ultragenyx Pharmaceutical 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ultragenyx Pharmaceutical wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Ultragenyx Pharmaceutical 并不在名单上。</p>
</div><p>While Ultragenyx Pharmaceutical currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ultragenyx Pharmaceutical 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Ultragenyx 制药（NASDAQ:RARE）在 Wall Street Zen 被上调至持有评级